Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection.
Jia-Qian ZhangSheng-Xiao ZhangJia WangJun QiaoMeng-Ting QiuXiao-Yan WuJun-Wen ChenChong GaoXiao-Feng LiPublished in: Current medical research and opinion (2022)
Patients with SLE had insufficiency of circulating lymphocyte subsets. This phenomenon was more obverse in those accompanying infection, suggesting the low concentration of lymphocytes may be used as indicators of high infection risk in SLE patients. Low-dose IL-2 induced expansion of Treg cells and NK cells, which may contribute to the restoration of immune homeostasis in SLE patients.
Keyphrases
- low dose
- end stage renal disease
- systemic lupus erythematosus
- ejection fraction
- chronic kidney disease
- peripheral blood
- newly diagnosed
- peritoneal dialysis
- high dose
- induced apoptosis
- oxidative stress
- rheumatoid arthritis
- patient reported outcomes
- endothelial cells
- bone marrow
- high glucose
- cell death
- cell proliferation
- diabetic rats